Skip to NavigationSkip to content

Top Ten most popular articles on this week!

Published on 16/11/18 at 10:48am

The Samsung scandal played a prominent role in this weeks’ top ten after the South Korean firm was delisted from the South Korean stock exchange over accounting violations. Equally Brexit chaos was central to this weeks’ news after a deal was revealed by Theresa May. The ongoing disruption has seen the resignation of a number of prominent players as backbench Brexiteer Jacob Rees Mogg called for a vote of no-confidence in Theresa May.

Our appointments section played a central role as well as pharma veterans Dave Tudor and Michael Boyd took on new roles. However this weeks’ top story covered NICE’s decision not to approve AstraZeneca’s cancer drug Olaparib on the basis that it is too expensive.  Check out this weeks’ top ten at!

10. Samsung BioLogics delisted over accounting violations

South Korean firm Samsung BioLogics has been delisted from the South Korean stock exchange.

9. Eisai's Lenvima wins over NICE in liver cancer in just three months

Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now be used routinely on the NHS in England and Wales for the first-line treatment of untreated, advanced, unresectable hepatocellular carcinoma (HCC).

8. German health minister Jens Spahn calls for faster adoption of biosimilars

Germany’s health minister Jens Spahn has called for faster uptake of biosimilars in an effort to cut cost of healthcare in Germany.

7. Samsung Biologics shares fall by 20% after Korean investigation

Shares in Korean firm Samsung BioLogics plummeted this week, falling by as much as 20% on Monday, after the South Korean Securities and Futures Commission (SFC) indicated that it will issue a ruling on the 14th of November over the company’s alleged violation of accounting rules.

6. Alabama's biggest insurer will no longer cover OxyContin prescriptions

The state of Alabama’s biggest insurer Blue Cross and Blue Shield will no long cover opioid painkiller OxyContin. The decision has come in response to the thousands of overdose deaths, caused by the drug each year.

5. Gilead appoint Pfizer and AbbVie veteran as VP of governmental affairs

Gilead have appointed Pfizer and AbbVie veteran Michael Boyd as VP of government affairs and policy strategies.

4. GSK veteran Dave Tudor joins MMIC in Scotland

GlaxoSmithKline veteran, Dave Tudor, is set to take on the role of Managing Director of the Medicines Manufacturing Innovation Centre (MMIC), a new manufacturing centre designed to increase the speed and cost effectiveness of the process through which medicines are brought to market.

3. No-deal Brexit preparations are a waste of time and money, according to Welsh industry representatives

The UK government’s request that pharmaceutical companies stockpile an additional six weeks’ worth of medicine, in preparation for a no-deal Brexit, is a waste of time and money, representatives for the Welsh pharmaceutical industry have said.

2. Phamaceutical trade lobby responds to Brexit deal

The Association of the British Pharmaceutical Industry (ABPI) has responded to Theresa May’s Brexit deal, after the government announced a 585 page draft withdrawal agreement has been agreed to by both the United Kingdom and the European Union.

1. NICE fail to recommend AstraZeneca's cancer drug Olaparib on cost effectiveness basis

Britain’s cost effectiveness body the National Institute of Health and Care Excellence (NICE) has chosen not to recommend AstraZeneca’s Olaparib for women with advanced ovarian cancer who had previously responded to platinum chemotherapy for six months or longer.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches